Phibro Animal Health (NASDAQ:PAHC) Rating Lowered to “Hold” at Zacks Research

Phibro Animal Health (NASDAQ:PAHC) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.68 EPS, FY2026 earnings at $3.04 EPS, Q2 2027 earnings at $0.84 EPS, Q3 2027 earnings at $0.75 EPS, Q4 2027 earnings at $0.80 EPS, FY2027 earnings at $3.17 EPS, Q1 2028 earnings at $0.81 EPS, Q2 2028 earnings at $0.91 EPS, Q3 2028 earnings at $0.81 EPS and FY2028 earnings at $3.34 EPS.

Several other brokerages have also recently issued reports on PAHC. Citigroup reduced their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Weiss Ratings cut Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $38.80.

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $33.26 on Thursday. The stock has a market cap of $1.35 billion, a P/E ratio of 14.27, a price-to-earnings-growth ratio of 0.51 and a beta of 0.61. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. The stock has a 50 day moving average of $50.29 and a 200-day moving average of $45.99. Phibro Animal Health has a 52 week low of $22.51 and a 52 week high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The firm had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, analysts expect that Phibro Animal Health will post 3.07 EPS for the current fiscal year.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total value of $219,562.72. Following the sale, the chief executive officer directly owned 56,152 shares in the company, valued at approximately $2,722,810.48. This trade represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 89,008 shares of company stock valued at $4,757,177 in the last quarter. Company insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cetera Investment Advisers raised its stake in shares of Phibro Animal Health by 2.7% during the first quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock valued at $608,000 after purchasing an additional 293 shares in the last quarter. 1620 Investment Advisors Inc. raised its stake in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares in the last quarter. Tudor Investment Corp ET AL raised its stake in shares of Phibro Animal Health by 3.4% during the third quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after purchasing an additional 338 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Phibro Animal Health by 2.9% during the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after purchasing an additional 363 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health News Roundup

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research raised its earnings estimates for multiple future periods, including FY2026, FY2027, and FY2028, while reiterating a Strong-Buy rating on Phibro Animal Health (NASDAQ:PAHC), which could support sentiment around the stock.
• Neutral Sentiment: Phibro announced it will participate in the Stifel Jaws & Paws Conference on May 27, giving management another opportunity to discuss strategy and outlook with investors. Article Title
• Negative Sentiment: Despite the upgraded earnings forecasts, the stock is still facing pressure from a Citi price-target cut to $44 from $62 earlier in the week, which may be weighing on shares and signaling concerns about sector conditions. Article Title

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.